30-day PMA supplement mechanism getting increased use at FDA, Burlington says.
This article was originally published in The Gray Sheet
Executive Summary
30-DAY PMA SUPPLEMENTS WILL BE USED MORE OFTEN BY FDA as part of an effort to improve efficiency in the agency's PMA supplement program, Bruce Burlington, director of FDA's Center for Devices and Radiological Health, says in a May 18 letter to device manufacturers. "When applicable, FDA will provide guidance to" holders of premarket approval application "on the types of changes that can be reported in a 30-day supplement and the data required to support those changes."
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.